Skip to main content
SpringerLink
Log in

RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker

  • Original Article
  • Published:
Tumor Biology

This article was retracted on 05 November 2016

Abstract

MicroRNAs (miRNAs) have a large number of various target genes in different cancer types, which may result in many biological functions. Thus, identifying the molecular mechanisms of miRNAs may effect on the complexity of cancer progression via regulation of gene. In the current study, we utilized real-time PCR to quantify the diction of miR-148b in trail hepatocellular carcinoma (HCC) specimen and normal tissues. Furthermore, we evaluated the relationship of miR-148b and clinicopathological features with survival of HCC patients. Therefore, we evaluated the level of miR-148b expression in 101 HCC patients and also in 40 normal control cases. The result suggested lower expression in tumor tissues than normal control tissues (0.96 ± 0.14; 1.84 ± 0.20, P < 0.05). Our findings suggest that the declined expression of miR-148b can considerably be linked to tumor node metastasis (TNM) stage (stages III and IV; P = 0.021) and vein invasion (P = 0.029). Nevertheless, miR-148b expression was not related to sex (P = 0.674), age (P = 0. 523), size of tumor (P = 0.507), liver cirrhosis, and histologic grade (P = 0.734). Survival analysis showed that low expression was remarkably related to overall survival (P = 0.012). Furthermore, multivariate survival test suggested that decline of miR-148b diction was linked to poor survival in HCC patients. Our results suggested that miR-148b is decreased in HCC. Therefore, we concluded that miR-148b may play its role in the prognosis of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  2. Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 2011;17:7574–83.

    Article  CAS  PubMed  Google Scholar 

  3. Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:885–9.

    Article  PubMed  Google Scholar 

  4. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.

    CAS  PubMed  Google Scholar 

  6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.

    Article  CAS  PubMed  Google Scholar 

  7. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010;11:136–46.

    Article  CAS  PubMed  Google Scholar 

  8. Zhao G, Zhang JG, Liu Y, Qin Q, Wang B, Tian K, et al. MiR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKalpha1. Mol Cancer Ther. 2013;12:83–93.

    Article  CAS  PubMed  Google Scholar 

  9. Azizi M, Teimoori-Toolabi L, Arzanani MK, Azadmanesh K, Fard-Esfahani P, Zeinali S. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 2014;15(4):419–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin N Am. 2010;24(4):899–919.

    Article  CAS  Google Scholar 

  11. Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol. 2014;31(6):984.

    Article  CAS  PubMed  Google Scholar 

  12. Cimino D, De Pitta C, Orso F, Zampini M, Casara S, Penna E, et al. MiR148b is a major coordinator of breast cancer progression in a relapseassociated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J. 2013;27:1223–35.

    Article  CAS  PubMed  Google Scholar 

  13. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 2011;10:1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Liu GL, Liu X, Lv XB, Wang XP, Fang XS, Sang Y. miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin Exp Med. 2014;7:1990–9.

    PubMed  PubMed Central  Google Scholar 

  15. Song Y, Xu Y, Wang Z, Chen Y, Yue Z, Gao P. MicroRNA-148b suppresses cell growth by targeting cholecystokinin-2 receptor in colorectal cancer. Int J Cancer. 2012;131(5):1042–51.

    Article  CAS  PubMed  Google Scholar 

  16. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013;132(7):1602–12.

    Article  CAS  PubMed  Google Scholar 

  17. Chang H, Zhou X, Wang ZN, Song YX, Zhao F, Gao P, et al. Increased expression of miR-148b in ovarian carcinoma and its clinical significance. Mol Med Rep. 2012;5(5):1277–80.

    CAS  PubMed  Google Scholar 

  18. Li L, Chen YY, Li SQ, Huang C, Qin YZ. Expression of miR-148/152 family as potential biomarkers in non-small-cell lung cancer. Med Sci Monit. 2015;21:1155–61.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Javad Javanbakht for his help with this manuscript.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Pathology, Be’sat Hospital, AJA University of Medical Sciences, Tehran, Iran

    Katayoun Ziari

  2. Center for Chemical Biology, Indian Institute of Chemical Technology (IICT), Tarnaka, Hyderabad, India

    Mojtaba Zarea

  3. Department of Radiology, Medical Imaging Center, Tehran University of Medical Sciences, Tehran, Iran

    Masoumeh Gity

  4. Department of Legal Medicine, AJA University of Medical Sciences, Tehran, Iran

    Amir Farshid Fayyaz

  5. Baqiyatallah University of Medical Sciences, Tehran, Iran

    Emad Yahaghi

  6. Young Researchers and Elite Club, Karaj Branch, Islamic Azad University, Karaj, Iran

    Ebrahim Khodaverdi Darian

  7. Department of Emergency Medicine, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Amir Masoud Hashemian

Authors
  1. Katayoun Ziari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mojtaba Zarea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masoumeh Gity
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amir Farshid Fayyaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emad Yahaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ebrahim Khodaverdi Darian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amir Masoud Hashemian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir Masoud Hashemian.

Additional information

This article has been retracted at the request of the Editor-in-Chief, the International Society of Oncology and BioMarkers (ISOBM) and the Publisher per the Committee on Publication Ethics guidelines. The article shows evidence of irregularities in authorship during the submission process, there is strong reason to believe that the peer review process was compromised and there are similarities with the following articles which were all submitted within a close timeframe:

Naeemeh Ghasemkhani, Sahar Shadvar, Yasamin Masoudi, Amir Jouya Talaei, Emad Yahaghi, Peyman Karimi Goudarzi, Ebrahim Shakiba, Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients. Diagnostic Pathology 2015, 10:164 DOI: 10.1186/s13000-015-0393-y Date received: 18 June 2015

Yasan Sadeghian, Zahra Kamyabi-Moghaddam, Seyed Mohamad Hossein Tabatabaei Nodushan, Samaneh Khoshbakht, Behnam Pedram, Emad Yahaghi, Aram Mokarizadeh, Mahdi Mohebbi, Profiles of tissue microRNAs; miR-148b and miR-25 serve as potential prognostic biomarkers for hepatocellular carcinoma. Tumor Biol. First Online: 25 July 2015 DOI: 10.1007/s13277-015-3799-y Date received: 1 July 2015

The retracted article was received: 16 June 2015

As such the validity of the content of this article cannot be verified.

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-016-5477-0.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ziari, K., Zarea, M., Gity, M. et al. RETRACTED ARTICLE: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker. Tumor Biol. 37, 5765–5768 (2016). https://doi.org/10.1007/s13277-015-3777-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3777-4

Keywords

Search

Navigation